COVID 19 and Febrile Neutropenia: Case Report and Systematic Review

Overview

Journal Travel Med Infect Dis

Specialty Infectious Diseases

Date 2022 Mar 10

PMID 35272019

Authors

Taner Kaya

Ahmet Dilek

Resat Ozaras

Ozlem Sahin Balcik

Hakan Leblebicioglu

Affiliations

Soon will be listed here.

Abstract

Objectives: In pandemic conditions, patients with febrile neutropenia are also at risk of COVID-19. Aim of this systematic review is to evaluate COVID-19 cases presented with febrile neutropenia and provide information regarding incidence, clinical course and prognosis.

Methods: We systematically searched on COVID-19 and febrile neutropenia cases in PubMed, SCOPUS and Web of Science.

Results: A total of 19 febrile neutropenic patients were analyzed. A male predominance was noted. Eleven cases had hematological malignancies. Fourteen of the cases were previously received chemotherapy. Five patients had severe neutropenia: 3 had hematologic cancer and none died. 17 (89.5%) cases have pulmonary involvement and seven of them had severe disease with acute respiratory distress syndrome (ARDS). Three cases with ARDS were died. 12 of them received G-CSF for treatment. Five cases were developed respiratory failure after G-CSF use. Overall mortality was 15.8%, while death was not observed in patients without malignancy and solid organ tumors, the mortality rate was 27% in cases with hematological malignancies.

Conclusion: In ongoing pandemic, febrile neutropenic patients should be precisely evaluated for COVID-19 disease. It should be remembered that there may not be typical signs and symptoms and laboratory findings of COVID-19 disease because of the immunosuppression.

Citing Articles

IL-8 Downregulation Mediates the Beneficial Effects of Infection-Induced Fever on Breast Cancer Prognosis.

Li H, Liang X, Ma J, Liu Q, Lin Y, Tang J J Inflamm Res. 2025; 18():405-419.

PMID: 39802515 PMC: 11725275. DOI: 10.2147/JIR.S496099.

Febrile neutropenia: Clinical approach to a controversial presentation of the COVID-19 era.

Hosseini M J Natl Cancer Cent. 2024; 3(4):251-253.

PMID: 39036663 PMC: 11256527. DOI: 10.1016/j.jncc.2023.08.005.

The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study.

Baskol Elik D, Kaya S, Alkan S, Demirdal T, Sener A, Kaya S Sci Rep. 2024; 14(1):5218.

PMID: 38433274 PMC: 10909849. DOI: 10.1038/s41598-024-55886-w.

Neutropenia after the coadministration of clozapine and nirmatrelvir-ritonavir in a patient with SARS-CoV-2 infection: A case report with a literature review.

Liu C, Goh K, Chen C Front Psychiatry. 2023; 13:1096006.

PMID: 36620672 PMC: 9810620. DOI: 10.3389/fpsyt.2022.1096006.

References

Figuero-Perez L, Olivares-Hernandez A, Escala-Cornejo R, Cruz-Hernandez J . Reply to A. Lasagna et al. JCO Oncol Pract. 2020; 16(11):772. DOI: 10.1200/OP.20.00640. View

Mertens J, Laghrib Y, Kenyon C . A Case of Steroid-Responsive, COVID-19 Immune Reconstitution Inflammatory Syndrome Following the Use of Granulocyte Colony-Stimulating Factor. Open Forum Infect Dis. 2020; 7(8):ofaa326. PMC: 7443106. DOI: 10.1093/ofid/ofaa326. View

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Riera R, Maria Bagattini A, Pacheco R, Pachito D, Roitberg F, Ilbawi A . Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review. JCO Glob Oncol. 2021; 7:311-323. PMC: 8081532. DOI: 10.1200/GO.20.00639. View

Yan X, Li F, Wang X, Yan J, Zhu F, Tang S . Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. J Med Virol. 2020; 92(11):2573-2581. PMC: 7283791. DOI: 10.1002/jmv.26061. View

Yarza R, Bover M, Paredes D, Lopez-Lopez F, Jara-Casas D, Castelo-Loureiro A . SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer. 2020; 135:242-250. PMC: 7275164. DOI: 10.1016/j.ejca.2020.06.001. View

Chong W, Saha B, Neu K . Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis. Infection. 2021; 50(1):43-56. PMC: 8475405. DOI: 10.1007/s15010-021-01701-x. View

Agirbasli H, Otlu B, Bilgen H, Durmaz R, Gedikoglu G . Epidemiological characteristics of fatal Candida krusei fungemia in immunocompromised febrile neutropenic children. Infection. 2007; 36(1):88-91. DOI: 10.1007/s15010-007-6246-1. View

10.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K . Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3):335-337. PMC: 7159000. DOI: 10.1016/S1470-2045(20)30096-6. View

11.

To K, Sridhar S, Chiu K, Hung D, Li X, Hung I . Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021; 10(1):507-535. PMC: 8006950. DOI: 10.1080/22221751.2021.1898291. View

12.

Leisman D, Ronner L, Pinotti R, Taylor M, Sinha P, Calfee C . Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020; 8(12):1233-1244. PMC: 7567529. DOI: 10.1016/S2213-2600(20)30404-5. View

13.

Lasagna A, Zuccaro V, Ferraris E, Rizzo G, Tancredi R, Pedrazzoli P . How to Use Prophylactic G-CSF in the Time of COVID-19. JCO Oncol Pract. 2020; 16(11):771-772. DOI: 10.1200/OP.20.00484. View

14.

Al-Makki A, Taber T . Neutropenic fever in COVID-19 in kidney transplant patient. Rev Med Virol. 2020; 31(1):1-2. DOI: 10.1002/rmv.2156. View

15.

Chong W, Saha B, Hu K, Chopra A . The incidence, clinical characteristics, and outcomes of pneumothorax in hospitalized COVID-19 patients: A systematic review. Heart Lung. 2021; 50(5):599-608. PMC: 8088235. DOI: 10.1016/j.hrtlng.2021.04.005. View

16.

Gagnier J, Kienle G, Altman D, Moher D, Sox H, Riley D . The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development. Glob Adv Health Med. 2014; 2(5):38-43. PMC: 3833570. DOI: 10.7453/gahmj.2013.008. View

17.

ONions J, Muir L, Zheng J, Rees-Spear C, Rosa A, Roustan C . SARS-CoV-2 antibody responses in patients with acute leukaemia. Leukemia. 2020; 35(1):289-292. PMC: 7724438. DOI: 10.1038/s41375-020-01103-2. View

18.

Garnett C, Foldes D, Bailey C, Nesr G, Hui T, Hinton R . Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom. Leuk Lymphoma. 2020; 62(2):469-472. DOI: 10.1080/10428194.2020.1838506. View

19.

Taha M, Sharma A, Soubani A . Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19. Respir Med Case Rep. 2020; 31:101231. PMC: 7515585. DOI: 10.1016/j.rmcr.2020.101231. View

20.

Ng K, Zhou S, Tan S, Ishak N, Goh Z, Chua Z . Understanding the Psychological Impact of COVID-19 Pandemic on Patients With Cancer, Their Caregivers, and Health Care Workers in Singapore. JCO Glob Oncol. 2020; 6:1494-1509. PMC: 7640379. DOI: 10.1200/GO.20.00374. View